HRP20161025T1 - Inhibitori proteaze hcv-a - Google Patents

Inhibitori proteaze hcv-a Download PDF

Info

Publication number
HRP20161025T1
HRP20161025T1 HRP20161025TT HRP20161025T HRP20161025T1 HR P20161025 T1 HRP20161025 T1 HR P20161025T1 HR P20161025T T HRP20161025T T HR P20161025TT HR P20161025 T HRP20161025 T HR P20161025T HR P20161025 T1 HRP20161025 T1 HR P20161025T1
Authority
HR
Croatia
Prior art keywords
heteroaryl
aryl
heterocycloalkyl
cycloalkyl
alkyl
Prior art date
Application number
HRP20161025TT
Other languages
English (en)
Inventor
Chen-Fu Liu
Kuang-Yuan Lee
Pei-Chin Cheng
Yo-Chin Liu
Pin Lo
Kuo-Feng Tseng
Chih-Ming Chen
Chi-Hsin Richard King
Chu-Chung Lin
Original Assignee
Taigen Biotechnology Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taigen Biotechnology Co., Ltd. filed Critical Taigen Biotechnology Co., Ltd.
Publication of HRP20161025T1 publication Critical patent/HRP20161025T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (15)

1. Tvar sljedeće formule: [image] pri čemu R1 je –H, -OH, C1-6 alkil, C1-6 alkoksil, C3-10 cikloalkil, C1-10 heterocikloalkil, aril, heteroaril, ili –NH-Z-R; gdje je R jednako H, ili je dio odabran između C1-6 alkila, C3-10 cikloalkila, C1-10 heterocikloalkila, arila i heteroarila, gdje je svaki od njih opcionalno mono-, di-, ili tri-supstituiran s halo, nitro, cijano, amino, C1-6 alkilom, C1-6 alkoksilom, C2-6 alkenilom, C2-6 alkinilom, arilom, ili heteroarilom; a Z je –C(O)-, -C(O)O-, -C(O)C(O)O-, -C(O)C(O)NH-, -C(O)NR'-, -OC(S)-, -C(S)NR'-, ili –C(NH)O-, R' je H, C1-6 alkil, C3-10 cikloalkil, C1-10 heterocikloalkil, aril, ili heteroaril; R2 je H, ili je dio odabran između C1-6 alkila, C3-10 cikloalkila, C1-10 heterocikloalkila, arila i heteroarila, gdje je svaki od njih opcionalno mono-, di-, ili tri-supstituiran s halo, nitro, cijano, amino, C1-6 alkilom, C1-6 alkoksilom, C2-6 alkenilom, C2-6 alkinilom, arilom, ili heteroarilom; A je N ili CH; U je –O-, -NH-, -NH(CO)-, -NHSO-, ili NHSO2-; W je –(CH2)m-, –NH(CH2)n-, –(CH2)nNH -, –O(CH2)n-, –(CH2)nO-, –S(CH2)n-, – (CH2)nS-, -SO-, –SO(CH2)n-, –(CH2)nSO-, –SO2(CH2)n-, ili –(CH2)nSO2-, m je 1, 2, ili 3 i n je 0, 1, ili 2; X je –O-, -S-, ili -NH-; i Y je [image] gdje je svaki V i T, nezavisno, -CH- ili –N-; svaki od A1 i A2, nezavisno je dio odabran između C4-10 cikloalkila, C1-10 heterocikloalkila, arila i heteroarila, gdje je svaki od njih opcionalno mono-, di-, ili tri-supstituiran s halo, nitro, cijano, amino, C1-6 alkilom, C1-6 alkoksilom, C2-6 alkenilom, C2-6 alkinilom, arilom, ili heteroarilom, ili opcionalno fuzioniran s C3-10 cikloalkilom, C2-10 heterocikloalkilom, arilom, ili heteroarilom; i Ri je H, halo, nitro, cijano, ili amino, ili je dio odabran između C1-6 alkila, C1-6 alkoksila, C2-6 alkenila, C2-6 alkinila, C3-10 cikloalkila, C1-10 heterocikloalkila, arila i heteroarila, svaki je od C1-6 alkila, C1-6 alkoksila, C2-6 alkenila i C2-6 alkinila opcionalno mono-, di-, ili tri-supstituiran s halo, nitro, cijano, amino, C1-6 alkilom, C1-6 alkoksilom, C2-6 alkenilom, C2-6 alkinilom, C3-10 cikloalkilom, C1-10 heterocikloalkilom, arilom, ili heteroarilom, i svaki od C3-10 cikloalkila, C1-10 heterocikloalkila, arila, ili heteroarila je opcionalno mono-, di-, ili tri-supstituiran s halo, nitro, cijano, amino, C1-6 alkilom, C1-6 alkoksilom, C2-6 alkenilom, C2-6 alkinilom, C3-10 cikloalkilom, C1-10 heterocikloalkilom, arilom, ili heteroarilom ili opcionalno fuzioniran s C3-10 cikloalkilom, C1-10 heterocikloalkilom, arilom, ili heteroarilom.
2. Tvar iz patentnog zahtjeva 1, pri čemu je A CH i W je - CH2CH2-, -OCH2-, -SCH2-, ili -SOCH2-.
3. Tvar sljedeće formule: [image] pri čemu R1 je –H, -OH, C1-6 alkil, C1-6 alkoksil, C3-10 cikloalkil, C1-10 heterocikloalkil, aril, heteroaril, ili –Z-R; gdje je R jednako H, ili je dio odabran između C1-6 alkila, C3-10 cikloalkila, C1-10 heterocikloalkila, arila i heteroarila, gdje je svaki od njih opcionalno mono-, di-, ili tri-supstituiran s halo, nitro, cijano, amino, C1-6 alkilom, C1-6 alkoksilom, C2-6 alkenilom, C2-6 alkinilom, arilom, ili heteroarilom; a Z je –C(O)-, -C(O)O-, -C(O)C(O)O-, -C(O)C(O)NH-, -C(O)NR'-, -OC(S)-, -C(S)NR'-, ili –C(NH)O-, R' je H, C1-6 alkil, C3-10 cikloalkil, C1-10 heterocikloalkil, aril, ili heteroaril; R2 je H, ili je dio odabran između C1-6 alkila, C3-10 cikloalkila, C1-10 heterocikloalkila, arila i heteroarila, gdje je svaki od njih opcionalno mono-, di-, ili tri-supstituiran s halo, nitro, cijano, amino, C1-6 alkilom, C1-6 alkoksilom, C2-6 alkenilom, C2-6 alkinilom, arilom, ili heteroarilom; A je CH ili N; U je –O-, -NH-, -NH(CO)-, -NHSO-, ili NHSO2-; W je –(CH2)m-, –NH(CH2)n-, –(CH2)nNH -, –O(CH2)n-, –(CH2)nO-, –S(CH2)n-, – (CH2)nS-, -SO-, –SO(CH2)n-, –(CH2)nSO-, –SO2(CH2)n-, ili –(CH2)nSO2-, m je 1, 2, ili 3 i n je 0, 1, ili 2; X je –O-, -S-, ili -NH-; Y je [image] gdje je svaki V i T, nezavisno, -CH- ili –N-; svaki od A1 i A2, nezavisno je dio odabran između C4-10 cikloalkila, C2-10 heterocikloalkila, arila i heteroarila, gdje je svaki od njih opcionalno mono-, di-, ili tri-supstituiran s halo, nitro, cijano, amino, C1-6 alkilom, C1-6 alkoksilom, C2-6 alkenilom, C2-6 alkinilom, arilom, ili heteroarilom, ili opcionalno fuzioniran s C3-10 cikloalkilom, C1-10 heterocikloalkilom, arilom, ili heteroarilom; i Ri je H, halo, nitro, cijano, ili amino, ili je dio odabran između C1-6 alkila, C1-6 alkoksila, C2-6 alkenila, C2-6 alkinila, C3-10 cikloalkila, C1-10 heterocikloalkila, arila i heteroarila, svaki je od C1-6 alkila, C1-6 alkoksila, C2-6 alkenila i C2-6 alkinila opcionalno mono-, di-, ili tri-supstituiran s halo, nitro, cijano, amino, C1-6 alkilom, C1-6 alkoksilom, C2-6 alkenilom, C2-6 alkinilom, C3-10 cikloalkilom, C1-10 heterocikloalkilom, arilom, ili heteroarilom, i svaki od C3-10 cikloalkila, C1-10 heterocikloalkila, arila, ili heteroarila je opcionalno mono-, di-, ili tri-supstituiran s halo, nitro, cijano, amino, C1-6 alkilom, C1-6 alkoksilom, C2-6 alkenilom, C2-6 alkinilom, C3-10 cikloalkilom, C1-10 heterocikloalkilom, arilom, ili heteroarilom ili opcionalno fuzioniran s C3-10 cikloalkilom, C1-10 heterocikloalkilom, arilom, ili heteroarilom; i [image] je jednostruka veza ili dvostruka veza.
4. Tvar iz patentnog zahtjeva 3, pri čemu je W - CH2CH2-, -OCH2-, -SCH2-, ili -SOCH2-; i [image] 4. je dvostruka veza.
5. Tvar sljedeće formule: [image] pri čemu R1 je –H, -OH, C1-6 alkil, C1-6 alkoksil, C3-10 cikloalkil, C1-10 heterocikloalkil, aril, heteroaril, –Z-R, ili –NH-Z-R; gdje je R jednako H, ili je dio odabran između C1-6 alkila, C3-10 cikloalkila, C1-10 heterocikloalkila, arila i heteroarila, gdje je svaki od njih opcionalno mono-, di-, ili tri-supstituiran s halo, nitro, cijano, amino, C1-6 alkilom, C1-6 alkoksilom, C2-6 alkenilom, C2-6 alkinilom, arilom, ili heteroarilom; a Z je –C(O)-, -C(O)O-, -C(O)C(O)O-, -C(O)C(O)NH-, -C(O)NR'-, -OC(S)-, -C(S)NR'-, ili –C(NH)O-, R' je H, C1-6 alkil, C3-10 cikloalkil, C1-10 heterocikloalkil, aril, ili heteroaril; A je N ili CH; U je –O-, -NH-, -NH(CO)-, -NHSO-, ili NHSO2-; W je –(CH2)m-, –NH(CH2)n-, –(CH2)nNH -, –O(CH2)n-, –(CH2)nO-, –S(CH2)n-, – (CH2)nS-, -SO-, –SO(CH2)n-, –(CH2)nSO-, –SO2(CH2)n-, ili –(CH2)nSO2-, m je 1, 2, ili 3 i n je 0, 1, ili 2; X je –O-, -S-, ili -NH-; Y je [image] gdje je svaki V i T, nezavisno, -CH- ili –N-; svaki od A1 i A2, nezavisno je dio odabran između C4-10 cikloalkila, C2-10 heterocikloalkila, arila i heteroarila, gdje je svaki od njih opcionalno mono-, di-, ili tri-supstituiran s halo, nitro, cijano, amino, C1-6 alkilom, C1-6 alkoksilom, C2-6 alkenilom, C2-6 alkinilom, arilom, ili heteroarilom, ili opcionalno fuzioniran s C3-10 cikloalkilom, C1-10 heterocikloalkilom, arilom, ili heteroarilom; i Ri je H, halo, nitro, cijano, ili amino, ili je dio odabran između C1-6 alkila, C1-6 alkoksila, C2-6 alkenila, C2-6 alkinila, C3-10 cikloalkila, C1-10 heterocikloalkila, arila i heteroarila, svaki je od C1-6 alkila, C1-6 alkoksila, C2-6 alkenila i C2-6 alkinila opcionalno mono-, di-, ili tri-supstituiran s halo, nitro, cijano, amino, C1-6 alkilom, C1-6 alkoksilom, C2-6 alkenilom, C2-6 alkinilom, C3-10 cikloalkilom, C1-10 heterocikloalkilom, arilom, ili heteroarilom, i svaki od C3-10 cikloalkila, C1-10 heterocikloalkila, arila, ili heteroarila je opcionalno mono-, di-, ili tri-supstituiran s halo, nitro, cijano, amino, C1-6 alkilom, C1-6 alkoksilom, C2-6 alkenilom, C2-6 alkinilom, C3-10 cikloalkilom, C1-10 heterocikloalkilom, arilom, ili heteroarilom ili opcionalno fuzioniran s C3-10 cikloalkilom, C1-10 heterocikloalkilom, arilom, ili heteroarilom; i je jednostruka veza ili dvostruka veza.
6. Tvar iz patentnog zahtjeva 5, pri čemu je A jednak CH; W je - CH2CH2-, -OCH2-, -SCH2-, ili -SOCH2-; i [image] 6. je dvostruka veza.
7. Tvar iz bilo kojeg od patentnih zahtjeva 1 do 6, pri čemu je X jednak O.
8. Tvar iz bilo kojeg od patentnih zahtjeva 1 do 7, pri čemu je U jednak –NHSO2-.
9. Tvar iz bilo kojeg od patentnih zahtjeva 1 do 8, pri čemu je Y [image] gdje je T jednak CH ili N i svaki od Ri, Rii, Riii, Riv i Rv, nezavisno je H, halo, nitro, cijano, amino, C1-6 alkil, C1-6 alkoksil, C2-6 alkenil, C2-6 alkinil, ili je dio odabran između C3-10 cikloalkila, C1-10 heterocikloalkila, arila i heteroarila, od kojih je svaki opcionalno mono-, di-, ili tri-supstituiran s halo, nitro, cijano, amino, C1-6 alkilom, C1-6 alkoksilom, C2-6 alkenilom, C2-6 alkinilom, arilom, ili heteroarilom, ili opcionalno fuzioniran s C3-10 cikloalkilom, C1-10 heterocikloalkilom, arilom, ili heteroarilom.
10. Tvar, gdje je tvar jedna od sljedećih tvari: [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image]
11. Tvar, pri čemu je tvar jedna od sljedećih tvari: [image] [image]
12. Farmaceutski sastav koji sadrži tvar iz bilo kojeg od patentnih zahtjeva 1-11 i farmaceutski prihvatljivi nosač.
13. Tvar iz bilo kojeg od patentnih zahtjeva 1-11 za uporabu u liječenju infekcije virusom hepatitisa C.
14. Tvar u skladu s patentnim zahtjevom 13 za uporabu u liječenju infekcije virusom hepatitisa C, pri čemu se tvar daje oralnim putem subjektu kojem je liječenje potrebno.
15. Tvar u skladu s patentnim zahtjevom 13 ili 14 za uporabu u liječenju infekcije virusom hepatitisa C, pri čemu se tvar primjenjuje jednom na dan.
HRP20161025TT 2009-09-15 2016-08-16 Inhibitori proteaze hcv-a HRP20161025T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2009/056937 WO2011034518A1 (en) 2009-09-15 2009-09-15 Hcv protease inhibitors
EP09849606.0A EP2477980B1 (en) 2009-09-15 2009-09-15 Hcv protease inhibitors

Publications (1)

Publication Number Publication Date
HRP20161025T1 true HRP20161025T1 (hr) 2016-11-04

Family

ID=43758907

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161025TT HRP20161025T1 (hr) 2009-09-15 2016-08-16 Inhibitori proteaze hcv-a

Country Status (21)

Country Link
US (1) US8389560B2 (hr)
EP (1) EP2477980B1 (hr)
JP (1) JP5702388B2 (hr)
KR (1) KR101670319B1 (hr)
AU (1) AU2009352688B2 (hr)
CA (1) CA2774145C (hr)
CY (1) CY1118136T1 (hr)
DK (1) DK2477980T3 (hr)
EA (1) EA022118B1 (hr)
ES (1) ES2588204T3 (hr)
HR (1) HRP20161025T1 (hr)
HU (1) HUE030402T2 (hr)
LT (1) LT2477980T (hr)
NZ (1) NZ599133A (hr)
PL (1) PL2477980T3 (hr)
PT (1) PT2477980T (hr)
SG (1) SG179566A1 (hr)
SI (1) SI2477980T1 (hr)
SM (1) SMT201600291B (hr)
WO (1) WO2011034518A1 (hr)
ZA (1) ZA201202631B (hr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
AP2011005695A0 (en) * 2008-10-15 2011-06-30 Intermune Inc Therapeutic antiviral poptides.
IN2012DN02693A (hr) * 2009-09-28 2015-09-04 Intermune Inc
WO2011041551A1 (en) * 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
US20110178107A1 (en) * 2010-01-20 2011-07-21 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
CA2821340A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN102911254A (zh) * 2011-08-02 2013-02-06 上海唐润医药科技有限公司 Hcv蛋白酶抑制剂
CA2863002A1 (en) 2012-01-11 2013-07-18 Abbvie Inc. Processes for making hcv protease inhibitors
EP3318566B1 (en) * 2012-09-20 2020-06-24 UDC Ireland Limited Azadibenzofurans for electronic applications
MX2015004411A (es) 2012-10-08 2016-04-06 Abbvie Inc Compuestos utiles para elaborar inhibidores de proteasa de virus de la hepatitis c (vhc).
KR20150074051A (ko) 2012-10-19 2015-07-01 브리스톨-마이어스 스큅 컴퍼니 C형 간염 바이러스 억제제
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
CN104557954A (zh) * 2013-10-16 2015-04-29 上海唐润医药科技有限公司 抗hcv的大环化合物
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN104447952A (zh) * 2014-12-11 2015-03-25 上海唐润医药科技有限公司 丙肝病毒蛋白酶抑制剂及其合成方法
CN108727417B (zh) * 2015-02-05 2021-10-08 爱博新药研发(上海)有限公司 多环化合物钠盐及其多晶型、制备方法及应用
WO2017221999A1 (en) 2016-06-22 2017-12-28 Idemitsu Kosan Co., Ltd. Specifically substituted benzofuro- and benzothienoquinolines for organic light emitting diodes
US10004719B1 (en) * 2017-05-30 2018-06-26 Taigen Biotechnology Co., Ltd. Solid dispersion formulation
CN110958880B (zh) * 2017-05-30 2023-08-08 东莞东阳光太景医药研发有限责任公司 固体分散制剂
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4555508A (en) 1984-03-02 1985-11-26 Usv Pharmaceutical Corp. Antihypertensive spiro-cyclic compounds
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
WO1997043310A1 (en) 1996-05-10 1997-11-20 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
US5876984A (en) 1996-09-25 1999-03-02 Shionogi & Co., Ltd Sequiterpene derivatives having antiviral activity
HU227742B1 (en) 1996-10-18 2012-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
ATE283865T1 (de) 1997-08-11 2004-12-15 Boehringer Ingelheim Ca Ltd Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
ES2281170T3 (es) 1998-03-31 2007-09-16 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas, particularmente proteasa ns3 del virus de la hepatitis c.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US20030073618A1 (en) 2001-02-08 2003-04-17 Kozhemyakin Leonid A. Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
US20020182647A1 (en) 2001-04-30 2002-12-05 Emmert-Buck Michael R. Histoscreen method
EP1404704B9 (en) 2001-07-11 2008-02-20 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2473070C (en) 2002-01-23 2009-10-13 Schering Corporation Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
PL373399A1 (en) 2002-04-11 2005-08-22 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
AU2003301959A1 (en) 2002-05-20 2004-06-03 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7601367B2 (en) 2002-05-28 2009-10-13 Mirus Bio Llc Compositions and processes using siRNA, amphipathic compounds and polycations
BR0315897A (pt) 2002-11-01 2008-05-13 Abbott Lab agentes antiinfecciosos
WO2004072243A2 (en) 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
ES2381548T3 (es) 2003-04-11 2012-05-29 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas, particularmente de la proteasa VHC NS3-NS4A
WO2004092161A1 (en) 2003-04-11 2004-10-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2004094452A2 (en) 2003-04-16 2004-11-04 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
EP2371834B1 (en) 2003-06-11 2016-02-17 Idera Pharmaceuticals, Inc. Stabilized immunomodulatory oligonucleotides
CN101724022A (zh) 2003-07-18 2010-06-09 沃泰克斯药物股份有限公司 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂
US20050119189A1 (en) 2003-09-18 2005-06-02 Cottrell Kevin M. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
MXPA06003141A (es) 2003-09-22 2006-06-05 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c.
DE602004031298D1 (de) 2003-09-26 2011-03-17 Schering Corp Makrocyclische inhibitoren der ns3-serinprotease des hepatitis-c-virus
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
CA2546290A1 (en) 2003-11-20 2005-06-09 Schering Corporation Depeptidized inhibitors of hepatitis c virus ns3 protease
TW200518746A (en) 2003-12-11 2005-06-16 Schering Corp Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
JP4682155B2 (ja) 2004-01-21 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスに対して活性な大環状ペプチド
CA2577831A1 (en) 2004-09-17 2006-03-30 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic hcv protease inhibitors
US20070207949A1 (en) 2005-06-02 2007-09-06 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
US20070237818A1 (en) 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
EP1898941A2 (en) 2005-06-02 2008-03-19 Schering Corporation Controlled-release formulation useful for treating disorders associated with hepatitis c virus
PE20080992A1 (es) * 2006-06-26 2008-08-06 Enanta Pharm Inc Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c
WO2008022006A2 (en) * 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis c virus protease inhibitors
US7605126B2 (en) 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US20080267917A1 (en) * 2007-04-26 2008-10-30 Deqiang Niu N-functionalized amides as hepatitis c serine protease inhibitors
WO2008134395A1 (en) * 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis c serine protease inhibitors
US20090005387A1 (en) * 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2009055335A2 (en) * 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors

Also Published As

Publication number Publication date
JP2013504616A (ja) 2013-02-07
US8389560B2 (en) 2013-03-05
AU2009352688B2 (en) 2014-04-17
SI2477980T1 (sl) 2017-01-31
JP5702388B2 (ja) 2015-04-15
SMT201600291B (it) 2016-11-10
US20110065737A1 (en) 2011-03-17
WO2011034518A1 (en) 2011-03-24
ES2588204T3 (es) 2016-10-31
EA022118B1 (ru) 2015-11-30
EA201270423A1 (ru) 2012-09-28
PT2477980T (pt) 2016-08-31
CA2774145A1 (en) 2011-03-24
EP2477980A1 (en) 2012-07-25
NZ599133A (en) 2013-10-25
DK2477980T3 (en) 2016-09-12
HUE030402T2 (en) 2017-05-29
EP2477980B1 (en) 2016-06-08
ZA201202631B (en) 2012-12-27
PL2477980T3 (pl) 2017-02-28
KR101670319B1 (ko) 2016-10-28
CA2774145C (en) 2015-10-27
AU2009352688A1 (en) 2012-04-26
EP2477980A4 (en) 2013-05-01
CY1118136T1 (el) 2017-06-28
KR20120110091A (ko) 2012-10-09
LT2477980T (lt) 2016-09-26
SG179566A1 (en) 2012-05-30

Similar Documents

Publication Publication Date Title
HRP20161025T1 (hr) Inhibitori proteaze hcv-a
HRP20211224T1 (hr) Derivati pirimidina za liječenje virusnih infekcija
HRP20131095T1 (hr) Derivati benzazepina korisni kao antagonisti vazopresina
AR046758A1 (es) Inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c
HRP20151075T1 (hr) Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino) propanoat
CA2536182A1 (en) Macrocyclic peptides active against the hepatitis c virus
HRP20180063T1 (hr) Lipidirani derivati imidazokinolina
HRP20230854T1 (hr) Fap-aktivirana terapeutska sredstva i s njima povezane uporabe
HRP20140493T1 (hr) Makrocikliäśki inhibitori serin proteaze hepatitisa c
PE20142345A1 (es) Compuestos beta-lactamicos sustituidos con amidina, su preparacion y uso como agentes antibacterianos
KR101479083B1 (ko) 피라진 유도체를 함유하는 의약조성물 및 피라진 유도체를 조합하여 사용하는 방법
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
PE20120993A1 (es) Derivados bifenilicos como antivirales
HRP20120866T1 (hr) Makrocikliäśni spojevi hinoksalina kao inhibitori hcv ns3 proteaze
HRP20171058T1 (hr) Derivati dipeptida lizinske glutaminske kiseline
JP2014520822A5 (hr)
PE20081792A1 (es) Inhibidores de serina proteasas
RS53588B1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
JP2010508362A5 (hr)
CA2338946A1 (en) Hepatitis c inhibitor tri-peptides
AR056556A1 (es) Imidazo(1,2-a)piridina con actividad antiproliferacion celular
BRPI0410714B8 (pt) derivados de quinazolina macrocíclicos, seu processo de preparação, composição farmacêutica que os compreende e uso
PE20080123A1 (es) Composiciones farmaceuticas que contienen vx-950 en el tratamiento de hepatitis c
PE20121479A1 (es) Inhibidores del virus de la hepatitis c
RS51394B (en) SUMPOR COMPOUNDS AS INHIBITORS OF NS3 SERINE PROTEASE HEPATITIS C VIRUS